Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute lymphoblastic leukemia (ALL)

5ʹ-Nucleotidase cytosolic II (NT5C2)

In vitro studies suggest inhibiting NT5C2 could help treat chemotherapy-resistant ALL. In the first study, whole-exome sequencing of 103 relapsed T cell and 35 B cell ALL samples identified 21 with mutations in NT5C2 that increased nucleotidase activity and were absent at diagnosis. In the second study, gain-of-function mutations in NT5C2 were identified in 2 of 10 pediatric patients with B cell ALL at relapse that were absent at diagnosis and in 5 of 61 additional relapsed samples in a follow-up study. Next steps include developing diagnostic assays to identify the mutations and developing NT5C2 inhibitors.

SciBX 6(8); doi:10.1038/scibx.2013.185
Published online Feb. 28, 2013

Patent application filed covering findings in first study; available for licensing for diagnostic and therapeutic applications

Patent and licensing status unavailable for findings in second study

Tzoneva, G. et al. Nat. Med.; published online Feb. 3, 2013;
doi:10.1038/nm.3078
Contact: Adolfo Ferrando, Columbia University, New York, N.Y.
e-mail:
af2196@columbia.edu


Meyer, J.A. et al. Nat. Genet.; published online Feb. 3, 2013;
doi:10.1038/ng.2558
Contact: William L. Carroll, NYU Cancer Institute, New York, N.Y.
e-mail:
william.carroll@nyumc.org